Nandan Padukone, PhD
Dr. Nandan Padukone is a biotech entrepreneur and executive with over 20 years of experience as a founder, CEO, C-suite leader, board member, and advisor. He has built and advanced therapeutics companies from discovery through clinical development, financing, and exit across oncology, metabolic disease, neurology, and immunology.
He currently advises venture firms, biotech companies, and academic venture offices on financing, pipeline strategy, and operations. Most recently, he helped launch Aurimi Therapeutics with Morningside Ventures, advancing an autoimmune program to Phase 2-ready and supporting multiple financings. He remains on Aurimi’s board and advises Morningside.
Previously, he founded the innovation and ventures office at Joslin Diabetes Center at Harvard Medical School, where he led spinouts, built strategic alliances, drove revenue growth, and expanded Joslin’s global footprint. Earlier, he supported financings, clinical development, and strategic transactions at NeuroBo Pharma, MD Anderson, and Altus Biologics.
He holds an MBA from the University of Denver and a PhD in Biochemical Engineering from NC State University.